Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Cerulean Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

24 Sep 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Cerulean Pharma Inc (CERU-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

25 Sep 2016 Thomson Reuters Stock Report 12 $25.00

ValuEngine Rating and Forecast Report for CERU

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

25 Sep 2016 ValuEngine, Inc. 11 $25.00

CERULEAN PHARMA INC (CERU=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

24 Sep 2016 Pechala's Reports 2 $25.00

Cerulean Pharma, Inc. (CERU) - Financial Analysis Review

Cerulean Pharma, Inc. (CERU) - Financial Analysis Review Summary Cerulean Pharma, Inc. (Cerulean) formerly Tempo Pharmaceutic...

12 Sep 2016 GlobalData 50 $300.00

Wright Investors Service Comprehensive Report for Cerulean Pharma Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

03 Sep 2016 Wright Reports 62 $75.00

CERU.OQ - Event Transcript of Cerulean Pharma Inc conference call, Aug. 17, 2016 / 4:30PM ET

Edited Event Transcript of CERU.OQ conference call, Aug. 17, 2016 / 4:30PM ET Boston, Aug 18, 2016 (Thomson StreetEvent...

17 Aug 2016 Thomson Reuters StreetEvents 11 $75.00

CERU.OQ - Event Transcript of Cerulean Pharma Inc conference call, Aug. 04, 2016 / 4:30PM ET

Edited Event Transcript of CERU.OQ conference call, Aug. 04, 2016 / 4:30PM ET Boston, Aug 7, 2016 (Thomson StreetEvents...

04 Aug 2016 Thomson Reuters StreetEvents 11 $75.00

CERULEAN PHARMA - UPDATE ON OVARIAN CANCER AND CRLX301

Cerulean recently presented the results on the Phase Ib trial of CRLX101 with weekly paclitaxel for the treatment of platinum...

24 Jun 2016 Edison Investment Research 6 $10.00

CERU.OQ - Event Transcript of Cerulean Pharma Inc conference call, Jun. 21, 2016 / 1:30PM ET

Edited Event Transcript of CERU.OQ conference call, Jun. 21, 2016 / 1:30PM ET New York, Jul 20, 2016 (Thomson StreetEve...

21 Jun 2016 Thomson Reuters StreetEvents 9 $75.00